Arca
Skip to content
Tools
Tools

CHRM1: Muscarinic acetylcholine receptor M1

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

  • Drugs that act on it: 32
  • Approved: 28
  • In phases 1 to 3: 4
  • Sponsors: 20

Who is on it, and how far along

Every drug ChEMBL records acting on CHRM1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 31
  • Other 1

Approved28

  • Atropine
  • Xanomeline
  • Glycopyrronium
  • Scopolamine
  • Pilocarpine
  • Trihexyphenidyl
  • Benztropine
  • Biperiden
  • Dicyclomine
  • Minaprine
  • Oxyphenonium
  • Procyclidine
  • Anisotropine
  • Cevimeline
  • Clidinium
  • Cycrimine
  • Diphemanil
  • Diphenidol
  • Ethopropazine
  • Hexocyclium
  • Isopropamide
  • Mepenzolate
  • Methixene
  • Methscopolamine
  • Oxyphencyclimine
  • Pirenzepine
  • Propantheline
  • Tridihexethyl

Phase 30

    Phase 24

    • ASM-024
    • MK-7622
    • TAK-071
    • Talsaclidine

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 25 of 32 act as: Muscarinic acetylcholine receptor M1 antagonist; the rest name their own mechanism.
      AtropineApprovedMagna Pharmaceuticals, Inc.Small moleculeAntagonist83
      XanomelineApprovedKaruna Therapeutics, Inc., a Bristol Myers Squibb companySmall moleculeAgonistMuscarinic acetylcholine receptor M1 agonist29
      GlycopyrroniumApprovedJourney MedicalSmall moleculeAntagonist22
      ScopolamineApprovedBaxter InternationalSmall moleculeAntagonist18
      PilocarpineApprovedAlconSmall moleculeAgonistMuscarinic acetylcholine receptor M1 agonist8
      TrihexyphenidylApprovedPfizerSmall moleculeAntagonist4
      BenztropineApprovedMerck & Co. (MSD)Small moleculeAntagonist3
      BiperidenApproved—Small moleculeAntagonist1
      DicyclomineWithdrawnApprovedAbbVieSmall moleculeAntagonist1
      MinaprineWithdrawnApprovedAstraZeneca PharmaceuticalsSmall moleculeAgonistMuscarinic acetylcholine receptor M1 agonist1
      OxyphenoniumApprovedNovartis PharmaceuticalsSmall moleculeAntagonist1
      ProcyclidineApprovedPfizerSmall moleculeAntagonist1
      AnisotropineApproved—Small moleculeAntagonist0
      CevimelineApprovedCosette PharmaceuticalsSmall moleculeAgonistMuscarinic acetylcholine receptor M1 agonist0
      ClidiniumApprovedRocheSmall moleculeAntagonist0
      CycrimineApprovedEli LillySmall moleculeAntagonist0
      DiphemanilApproved—Small moleculeAntagonist0
      DiphenidolApprovedGSKSmall moleculeAntagonist0
      EthopropazineApprovedPfizerSmall moleculeAntagonist0
      HexocycliumApproved—Small moleculeAntagonist0
      IsopropamideApproved—Small moleculeAntagonist0
      MepenzolateApprovedSanofiSmall moleculeAntagonist0
      MethixeneApprovedNovartis PharmaceuticalsSmall moleculeAntagonist0
      MethscopolamineApprovedSandozSmall moleculeAntagonist0
      OxyphencyclimineApprovedPfizerSmall moleculeAntagonist0
      PirenzepineApprovedWinSanTor, IncSmall moleculeAntagonist0
      PropanthelineApprovedTakeda Pharmaceuticals USASmall moleculeAntagonist0
      TridihexethylApprovedPfizerSmall moleculeAntagonist0
      ASM-024Phase 2Asmacure LtéeOtherAntagonist0
      MK-7622Phase 2Merck & Co. (MSD)Small moleculePositive allosteric modulatorMuscarinic acetylcholine receptor M1 positive allosteric modulator0
      TAK-071Phase 2Takeda Pharmaceuticals USASmall moleculePositive allosteric modulatorMuscarinic acetylcholine receptor M1 positive allosteric modulator0
      TalsaclidinePhase 2Boehringer Ingelheim PharmaceuticalsSmall moleculeAgonistMuscarinic acetylcholine receptor M1 agonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 50 in all, from ClinicalTrials.gov.
      Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)Glycopyrronium—Not yet recruitingAstraZenecaNov 12, 2026
      BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard TreatmentAtropineNot applicableNot yet recruitingSingapore National Eye CentreNov 6, 2026
      Oral Gabapentin Versus Intravenous Neostigmine/Atropine Versus Combination of Both for Prevention of PDPHAtropinePhase 2 / Phase 3RecruitingAssiut UniversityNov 4, 2026
      Segmental Thoracic vs Lumbar Spinal: Recovery After Elective CesareanAtropineNot applicableNot yet recruitingAdiyaman University Research HospitalNov 4, 2026
      Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationAtropineNot applicableRecruitingChina National Center for Cardiovascular DiseasesOct 16, 2026
      Prospective Trial of [18F]AlF-FAPI-74 for PET Imaging of Fibroblast Activation Protein in Patients With EndometriosisScopolamineNot applicableRecruitingUniversitaire Ziekenhuizen KU LeuvenOct 15, 2026
      Early Intervention for High Risk Premyopic ChildrenAtropinePhase 2Not yet recruitingNational Yang Ming Chiao Tung University HospitalOct 7, 2026
      Pain After Scheduled Cesarean Delivery: Spinal Morphine With or Without Levobupivacaine Wound InfiltrationScopolamine—Not yet recruitingFundación Santa Fe de BogotaOct 6, 2026
      Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaGlycopyrroniumPhase 3Not yet recruitingChiesi Farmaceutici S.p.A.Oct 5, 2026
      Control of Myopia in Young Children Using H.O.P.E. Lenses Combined With 0.02% Atropine Eye DropsAtropineNot applicableNot yet recruitingRuihua WeiSep 29, 2026
      PREterm Infants With Bronchial Obstruction - Prospective Study of Efficacy and Safety of Inhaled TiotropiumScopolaminePhase 4Not yet recruitingGeneral University Hospital, PragueSep 18, 2026
      AI-Stratified Myopia Control for Children in Remote AreasAtropineNot applicableNot yet recruitingShanghai Eye Disease Prevention and Treatment CenterSep 17, 2026
      Hyoscine Butylbromide During Transcystic Papillary Balloon Dilation for CholedocholithiasisScopolamineNot applicableRecruitingRiga East Clinical University HospitalSep 11, 2026
      Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)AtropinePhase 2RecruitingRehan AhmedSep 11, 2026
      Comparison of Benzhexol and Procyclidine for Tremor in Tremor-Predominant Parkinson's DiseaseProcyclidine, TrihexyphenidylNot applicableRecruitingsafia banoSep 9, 2026
      A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With SchizophreniaXanomeline—Not yet recruitingZai Lab (Shanghai) Co., Ltd.Sep 3, 2026
      Long-Term Real-World Safety of Cobenfy in Adults With SchizophreniaXanomeline—Active, not recruitingBristol-Myers SquibbAug 24, 2026
      Human Cognition During Surgery: Stimulation-based and Cholinergic ModulationXanomelineEarly phase 1Not yet recruitingUniversity of Texas Southwestern Medical CenterJul 23, 2026
      Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaXanomelinePhase 3RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb companyJul 7, 2026
      Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersXanomelinePhase 4RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb companyJul 2, 2026
      BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])GlycopyrroniumPhase 4RecruitingChiesi Farmaceutici S.p.A.Jun 24, 2026
      Efficacy of Pregabalin for Patients With Irritable Bowel SyndromeDicyclomineNot applicableRecruitingBeijing Tiantan HospitalJun 9, 2026
      The Impact of Cobenfy Maintenance on Cocaine's EffectsXanomelinePhase 1 / Phase 2RecruitingJoshua A. Lile, Ph.D.Jun 3, 2026
      An Exploratory Study on Triple Inhaler Therapy in Patients With Early Lung Function ImpairmentGlycopyrroniumNot applicableNot yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityMay 19, 2026
      Multimodal Anesthesia in Robotic Laparoscopic NephrectomyScopolamineNot applicableRecruitingFundacio PuigvertApr 30, 2026
      Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonistsGlycopyrroniumPhase 3RecruitingChiesi Farmaceutici S.p.A.Apr 23, 2026
      A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With AsthmaGlycopyrroniumPhase 2RecruitingAstraZenecaApr 13, 2026
      Imaging of Endometriosis With Total-body PET-CT (PET-Endo)Scopolamine—RecruitingUniversity of EdinburghApr 13, 2026
      Contamination of Young Children Hair During Acute Cannabis IntoxicationPilocarpineNot applicableRecruitingUniversity Hospital, ToulouseApr 13, 2026
      Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)Glycopyrronium—RecruitingChiesi Slovenija, d.o.o.Mar 24, 2026
      Representation of Spatiotemporal Information in Human Episodic Memory and NavigationScopolamineEarly phase 1Enrolling by invitationUniversity of ArizonaFeb 20, 2026
      A PET/MRI Study of Cobenfy on Dopamine Transmission in SchizophreniaXanomelinePhase 1 / Phase 2RecruitingNew York State Psychiatric InstituteFeb 20, 2026
      A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsXanomelinePhase 3RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb companyFeb 20, 2026
      Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR FunctionPilocarpineNot applicableNot yet recruitingEmory UniversityFeb 17, 2026
      Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD PatientsGlycopyrronium—RecruitingChiesi Farmaceutica Ltda.Feb 12, 2026
      A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy ProceduresScopolamineNot applicableNot yet recruitingShanghai Jiao Tong University School of MedicineDec 9, 2025
      Quality of Life in Presbyopic Patients Who Are Treated With QlosiPilocarpinePhase 4RecruitingSouthern College of OptometryAug 8, 2025
      KERMIT: Sweat Patch for Early Kidney Disease DetectionPilocarpineNot applicableNot yet recruitingUniversity of IoanninaJul 2, 2025
      Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in ChildrenPilocarpineNot applicableNot yet recruitingMansoura UniversityJun 10, 2025
      A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerMinaprinePhase 2Active, not recruitingAstraZenecaJan 27, 2025
      Anticholinergic Deprescription in SchizophreniaBenztropine, TrihexyphenidylPhase 4RecruitingDeepak K. Sarpal, M.D.Aug 20, 2024
      Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral PalsyTrihexyphenidylPhase 1RecruitingChildren's Mercy Hospital Kansas CityAug 15, 2024
      Accelerating TMS for Cervical DystoniaTrihexyphenidylPhase 2Enrolling by invitationDuke UniversityMar 25, 2024
      Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic DisorderBenztropinePhase 4RecruitingAarhus University HospitalJan 30, 2024
      Methadone to Treat Painful Chemotherapy Induced Peripheral NeuropathyOxyphenoniumPhase 2 / Phase 3RecruitingUniversity of British ColumbiaMar 27, 2023
      Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat TrialPilocarpineNot applicableEnrolling by invitationVastra Gotaland RegionDec 16, 2021
      Biperiden Trial for Epilepsy PreventionBiperidenPhase 3RecruitingHospital Sirio-LibanesJun 30, 2021
      CLOZAPINE Response in Biotype-1BenztropinePhase 4RecruitingUniversity of Texas Southwestern Medical CenterOct 8, 2020
      Pilocarpine Use After Kahook GoniotomyPilocarpinePhase 3RecruitingMontefiore Medical CenterMay 1, 2019
      Optimal Treatment Protocol for Selective Laser TrabeculoplastyPilocarpineNot applicableActive, not recruitingVastra Gotaland RegionJan 9, 2019

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Parkinson disease
      0.67
      Myopia
      0.59
      Asthma
      0.59
      Gastrointestinal disease
      0.58
      Peptic ulcer disease
      0.58
      Mydriasis
      0.55
      Nausea
      0.54

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      CHRM1

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL216, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P11229, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.